<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862823</url>
  </required_header>
  <id_info>
    <org_study_id>F081030003</org_study_id>
    <nct_id>NCT00862823</nct_id>
  </id_info>
  <brief_title>The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers</brief_title>
  <official_title>The Stability and Bioequivalence of Tenofovir, Emtricitabine and Efavirenz (Atripla) in an Extemporaneously Prepared Oral Liquid Formulation Compared With the Commercially Available Tablet Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the average bioequivalence of tenofovir,
      emtricitabine and efavirenz in an extemporaneously prepared oral liquid formulation (test
      formulation) compared with the commercially available tablet formulation (reference
      formulation). The study is designed as an open-label, randomized, 2-period, 2-treatment,
      2-sequence, single-dose intensive pharmacokinetic study conducted in healthy volunteers.
      Subjects will be randomized to receive the Atripla tablet (reference formulation) or the
      Atripla tablet crushed and mixed in OraSweet solution (test formulation) on Study Day 1.
      Subjects will undergo a 12-hour intensive pharmacokinetic evaluation after ingesting a single
      dose of either the test or reference formulation. On days 2 and 3, subjects will provide an
      additional pharmacokinetic sample 24 and 48 hours post dose, respectively. Subjects will
      complete a washout period from day 2 to day 14 during which no study drugs will be ingested.
      On day 14, subjects will ingest either the reference or test formulation (opposite of the
      formulation received on Study Day 1). All subjects will undergo another 12-hour intensive
      pharmacokinetic evaluation. On days 16 and 17 subjects will provide an additional
      pharmacokinetic sample 24 and 48 hours post dose, respectively. Adverse events and
      concomitant medications will be documented throughout the study.

      The sample size is 16 and is based upon a 10% drop-out rate (i.e. due to lost to follow-up,
      treatment discontinuation, etc.). Since the investigators are expecting two subjects not to
      complete the study, the investigators expect 14 evaluable subjects. If the discontinuation
      rate is greater than 10%, the investigators will continue to enroll until the investigators
      get 14 evaluable subjects. The primary endpoint is to determine average bioequivalence for
      test and reference formulations of tenofovir, emtricitabine and efavirenz according to the
      FDA guidance on bioequivalence testing. The ratio of the test to reference formulation mean
      Cmax and AUC24 for each drug and the 90% confidence interval around each mean ratio will be
      determined. Average bioequivalence will be met if 90% confidence intervals around the Cmax,
      and AUC24 mean ratios for each drug falls within the FDA's predefined limits of 0.80 to 1.25.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz</measure>
    <time_frame>17 days</time_frame>
    <description>The area under the concentration time curve for tenofovir, emtricitabine and efavirenz</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration for Tenofovir, Emtricitabine and Efavirenz</measure>
    <time_frame>17 days</time_frame>
    <description>The maximum concentration for tenofovir, emtricitabine and efavirenz</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Atripla Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug exposure after administration of Atripla Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atripla Liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug exposure after administration of an extemporaneously prepared liquid formulation of Atripla</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir, emtricitabine and efavirenz fixed dose tablet</intervention_name>
    <description>Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz</description>
    <arm_group_label>Atripla Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir, emtricitabine and efavirenz tablet added to solution</intervention_name>
    <description>Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz</description>
    <arm_group_label>Atripla Liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥19 and ≤65, HIV-1 negative, Able to give consent, Non-smoking,Screening EKG
             within normal limits, Females of childbearing potential must have a negative pregnancy
             test at screening and agree to use a double-barrier method of contraception throughout
             the study period.

        Exclusion Criteria:

          -  Subjects receiving any prescription or over-the-counter products will be excluded from
             the study. Subjects using any form of recreational drugs will be excluded. Subjects
             who have any of the following laboratory abnormalities within 30 days of study entry
             will be excluded:

               -  SGOT (AST)/SGPT (ALT) &gt; 3 x upper limits of normal (ULN) (Subjects with liver
                  disease are allowed to enroll unless their AST/ALT levels are greater than three
                  times ULN)

               -  Bilirubin &gt; 2.5 x ULN

               -  Amylase &gt; 2 x ULN

               -  Absolute Neutrophil Count &lt; 1000 x 103/L

               -  Hgb &lt; 9.0 g/dl

               -  Platelets &lt;50,000 cells/mm3

               -  Serum Creatinine &gt; 2.5 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer R King, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>King J, McCall M, Cannella A, Markiewicz MA, James A, Hood CB, Acosta EP. A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet. J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):e130-2.</citation>
    <PMID>22046602</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <results_first_submitted>February 16, 2012</results_first_submitted>
  <results_first_submitted_qc>August 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jennifer King</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy volunteers recruited in Birmingham, AL from March 2009 and August 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tablet First, Then Liquid</title>
          <description>Single dose of Atripla tablet in first intervention period and Single dose of Atripla liquid in second intervnetion period</description>
        </group>
        <group group_id="P2">
          <title>Liquid First, Then Tablet</title>
          <description>Single dose of Atripla liquid in first intervention period and single dose of Atripla tablet in second intervnetion period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 2 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive tablet first and liquid first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz</title>
        <description>The area under the concentration time curve for tenofovir, emtricitabine and efavirenz</description>
        <time_frame>17 days</time_frame>
        <population>US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug ProductsdGeneral Considerations. Rockville, MD: United States Food and Drug Administration Center for Drug Evaluation and Research.</population>
        <group_list>
          <group group_id="O1">
            <title>Atripla Tablet</title>
            <description>Includes groups randomized to receive tablet first and liquid first</description>
          </group>
          <group group_id="O2">
            <title>Atripla Liquid</title>
            <description>Includes groups randomized to receive tablet first and liquid first</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz</title>
          <description>The area under the concentration time curve for tenofovir, emtricitabine and efavirenz</description>
          <population>US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug ProductsdGeneral Considerations. Rockville, MD: United States Food and Drug Administration Center for Drug Evaluation and Research.</population>
          <units>mg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Efavirenz AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="57.5"/>
                    <measurement group_id="O2" value="56.7" spread="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emtricitabine AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="24.7"/>
                    <measurement group_id="O2" value="10.8" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenofovir AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="29.2"/>
                    <measurement group_id="O2" value="2.2" spread="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size was determined so there was an 80% chance that a 90% pairwise interval for 2 equivalent formulations would satifsy the FDA criteria for AUC and Cmax of log (0.8), log (1.2).</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Bioequivalent measurew were log-transformed</p_value_desc>
            <method>log transformation</method>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>90</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration for Tenofovir, Emtricitabine and Efavirenz</title>
        <description>The maximum concentration for tenofovir, emtricitabine and efavirenz</description>
        <time_frame>17 days</time_frame>
        <population>US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug ProductsdGeneral Considerations. Rockville, MD: United States Food and Drug Administration Center for Drug Evaluation and Research.</population>
        <group_list>
          <group group_id="O1">
            <title>Atripla Tablet</title>
            <description>Includes groups randomized to receive tablet first and liquid first</description>
          </group>
          <group group_id="O2">
            <title>Atripla Liquid</title>
            <description>Includes groups randomized to receive tablet first and liquid first</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration for Tenofovir, Emtricitabine and Efavirenz</title>
          <description>The maximum concentration for tenofovir, emtricitabine and efavirenz</description>
          <population>US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug ProductsdGeneral Considerations. Rockville, MD: United States Food and Drug Administration Center for Drug Evaluation and Research.</population>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Efavirenz Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="39"/>
                    <measurement group_id="O2" value="1.3" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emtricitabine Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="32.3"/>
                    <measurement group_id="O2" value="2.1" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenofovir Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="27.7"/>
                    <measurement group_id="O2" value="0.2" spread="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive tablet first and liquid first</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Efavirenz exposure was highly variable and relative bioequivalence for efavirenz may have been more appropriately assessed with a larger sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jennifer King</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-2696</phone>
      <email>jenking@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

